MIA DAVETA: Open Payments
NPI 1932896586 · SAINT PETERS, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,389 in 166 payments from 12 companies in 2025. Trend: 2023 $964 · 2024 $1,548 · 2025 $2,389
Food & beverage: $2,329Education: $59
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 39 | $516 |
| Vanda Pharmaceuticals Inc. | 31 | $473 |
| Otsuka America Pharmaceutical, Inc. | 22 | $381 |
| ABBVIE INC. | 22 | $236 |
| Alkermes, Inc. | 18 | $233 |
| E.R. Squibb & Sons, L.L.C. | 12 | $194 |
| Teva Pharmaceuticals USA, Inc. | 10 | $136 |
| Lundbeck LLC | 3 | $68 |
| Neurocrine BioSciences, Inc. | 3 | $53 |
| Supernus Pharmaceuticals, Inc. | 2 | $36 |
Products named: CAPLYTA, FANAPT, REXULTI, VRAYLAR, ARISTADA, COBENFY, UZEDY, AUSTEDO XR.
Industry payments across MO — which companies pay providers there.
